MOLOGNI LUCA

Ruolo: 
Ricercatore a tempo determinato
Settore scientifico disciplinare: 
BIOLOGIA APPLICATA (BIO/13)
Telefono: 
0264488148
0264488059
Stanza: 
U08, Piano: P04, Stanza: 4043
Via Cadore, 48 - 20900 MONZA
U8, Piano: IV, Stanza: LABORATORIO 4.10
Via Cadore, 48 - 20900 MONZA

Pubblicazioni

  • Crespiatico, I., Bossi, E., Brioschi, F., Piazza, R., Mologni, L., & Gambacorti‐Passerini, C. (2020). An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. CLINICAL CASE REPORTS, 8(1), 71-74. Dettaglio
  • Bossi, E., Aroldi, A., Brioschi, F., Steidl, C., Baretta, S., Renso, R., et al. (2020). Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. AMERICAN JOURNAL OF HEMATOLOGY. Dettaglio
  • Bossi, E., Brioschi, F., Steidl, C., Baretta, S., Cantu, S., Verga, L., et al. (2019). Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy. Intervento presentato a: Congress of the Italian-Society-of-Hematology, Rome, Italy. Dettaglio
  • Sharma, G., Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., et al. (2019). A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. JOURNAL OF THORACIC ONCOLOGY, 14(11), e257-e259. Dettaglio
  • Menotti, M., Ambrogio, C., Cheong, T., Pighi, C., Mota, I., Cassel, S., et al. (2019). Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. NATURE MEDICINE, 25(1), 130-140. Dettaglio